scholarly article | Q13442814 |
P50 | author | Lars A. Akslen | Q11983239 |
P2093 | author name string | O Straume | |
P2860 | cites work | Induction of lasting complete regression of preformed distinct solid tumors by targeting the tumor vasculature using two new anti-endoglin monoclonal antibodies | Q74484401 |
Expression of growth factors, growth inhibiting factors, and their receptors in invasive breast cancer. I: An inventory in search of autocrine and paracrine loops | Q74532039 | ||
Tumoural vascularity as a prognostic factor in cancer patients: the evidence continues to grow | Q74592128 | ||
Mutant p53 correlates with reduced expression of thrombospondin-1, increased angiogenesis, and metastatic progression in melanoma | Q74624644 | ||
Expression pattern of vascular endothelial growth factor isoform is closely correlated with tumour stage and vascularisation in renal cell carcinoma | Q77349652 | ||
Elevated expression of endoglin, a component of the TGF-beta-receptor complex, correlates with proliferation of tumor endothelial cells | Q77392041 | ||
Vascular endothelial growth factor upregulates the expression of matrix metalloproteinases in vascular smooth muscle cells: role of flt-1 | Q77426354 | ||
Up-regulation of endoglin on vascular endothelial cells in human solid tumors: implications for diagnosis and therapy | Q77555510 | ||
Progression-related expression of beta3 integrin in melanomas and nevi | Q77763337 | ||
Angiogenesis is prognostically important in vertical growth phase melanomas | Q78062978 | ||
Expression of vascular endothelial growth factor (VEGF) and its receptors is regulated in eyes with intra-ocular tumours | Q93921697 | ||
Adhesive proteins and the hematogenous spread of cancer | Q41288940 | ||
Peripheral blood T lymphocytes and lymphocytes infiltrating human cancers express vascular endothelial growth factor: a potential role for T cells in angiogenesis. | Q41295542 | ||
Thrombospondin as a regulator of angiogenesis | Q41322625 | ||
Transfection of thrombospondin 1 complementary DNA into a human breast carcinoma cell line reduces primary tumor growth, metastatic potential, and angiogenesis. | Q41411589 | ||
Angiogenesis: new aspects relating to its initiation and control. | Q41543929 | ||
Development of retinal vasculature is mediated by hypoxia-induced vascular endothelial growth factor (VEGF) expression by neuroglia | Q41677354 | ||
Extent of vascularization as a prognostic indicator in thin (< 0.76 mm) malignant melanomas | Q41773010 | ||
The vascularity of cutaneous melanoma: a quantitative histological study of lesions 0.85-1.25 mm in thickness | Q42373298 | ||
Transition of horizontal to vertical growth phase melanoma is accompanied by induction of vascular endothelial growth factor expression and angiogenesis | Q42454817 | ||
Thrombospondin-1 and its CSVTCG-specific receptor in wound healing and cancer | Q42455654 | ||
Expression of vascular endothelial growth factor and its receptors flt and KDR in ovarian carcinoma. | Q42805124 | ||
The constitutive level of vascular endothelial growth factor (VEGF) is more important than hypoxia-induced VEGF up-regulation in the angiogenesis of human melanoma xenografts | Q43202381 | ||
Prognostic significance of angiogenesis and Ki-67, p53, and p21 expression: a population-based endometrial carcinoma study | Q44697724 | ||
Angiogenesis during tumor progression in human malignant melanoma | Q45818662 | ||
Upregulation of endoglin (CD105) expression during childhood brain tumor-related angiogenesis. Anti-angiogenic therapy | Q46138494 | ||
Thrombospondin-1 expression in bladder cancer: association with p53 alterations, tumor angiogenesis, and tumor progression | Q46439216 | ||
Expression of vascular endothelial growth factor in human gastric carcinomas | Q47698165 | ||
Restoration of wild-type p16 down-regulates vascular endothelial growth factor expression and inhibits angiogenesis in human gliomas. | Q48136880 | ||
Vascular permeability factor/vascular endothelial growth factor (VPF/VEGF) delays and induces escape from senescence in human dermal microvascular endothelial cells | Q48717167 | ||
Tumor vascularity as a prognostic indicator in intermediate-thickness (0.76-4 mm) cutaneous melanoma. A quantitative assay. | Q50994893 | ||
Angiogenesis and malignant melanoma. Angiogenesis is related to the development of vertical (tumorigenic) growth phase. | Q53444387 | ||
Expression and functional significance of vascular endothelial growth factor receptors in human tumor cells. | Q55476304 | ||
Analysis of the p16 gene (CDKN2) as a candidate for the chromosome 9p melanoma susceptibility locus | Q57269211 | ||
Mutations in the CDKN2A ( p16INK4a ) gene in microdissected sporadic primary melanomas | Q57664941 | ||
Thrombospondins I and II messenger RNA expression in lung carcinoma: relationship with p53 alterations, angiogenic growth factors, and vascular density | Q59219543 | ||
The Vascular Endothelial Growth Factor Receptor Flt-1 Mediates Biological Activities | Q59261168 | ||
The heparin binding 25 kDa fragment of thrombospondin-1 promotes angiogenesis and modulates gelatinase and TIMP-2 production in endothelial cells | Q60043731 | ||
Angiogenesis and tumor progression of melanoma. Quantification of vascularity in melanocytic nevi and cutaneous malignant melanoma | Q67900089 | ||
Integrin distribution in malignant melanoma: association of the beta 3 subunit with tumor progression | Q68547014 | ||
Thrombospondin, a potentiator of tumor cell metastasis | Q69120538 | ||
Human melanoma cells but not normal melanocytes express vascular endothelial growth factor receptors | Q70575554 | ||
Wild-type p53 and v-Src exert opposing influences on human vascular endothelial growth factor gene expression | Q70786899 | ||
Expression of vascular permeability factor/vascular endothelial growth factor by melanoma cells increases tumor growth, angiogenesis, and experimental metastasis | Q70866384 | ||
Melanoma cell lines express VEGF receptor KDR and respond to exogenously added VEGF | Q70882002 | ||
Beta3 integrin expression in melanoma predicts subsequent metastasis | Q71139754 | ||
Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1 | Q71644976 | ||
Expression of the extracellular matrix molecule thrombospondin inversely correlates with malignant progression in melanoma, lung and breast carcinoma cell lines | Q72721355 | ||
Up-regulation of ephrin-A1 during melanoma progression | Q73032207 | ||
Cell-retained isoforms of vascular endothelial growth factor (VEGF) are correlated with poor prognosis in osteosarcoma | Q73112514 | ||
Signals leading to apoptosis-dependent inhibition of neovascularization by thrombospondin-1 | Q73308215 | ||
Sequential development of an angiogenic phenotype by human fibroblasts progressing to tumorigenicity | Q73309958 | ||
Loss of nuclear p16 protein expression correlates with increased tumor cell proliferation (Ki-67) and poor prognosis in patients with vertical growth phase melanoma | Q73803410 | ||
Combined analysis of p53 and vascular endothelial growth factor expression in colorectal carcinoma for determination of tumor vascularity and liver metastasis | Q73841963 | ||
Angiogenic balance in human melanoma: expression of VEGF, bFGF, IL-8, PDGF and angiostatin in relation to vascular density of xenografts in vivo | Q73863756 | ||
Vascular permeability factor (vascular endothelial growth factor) expression and angiogenesis in patients with ductal carcinoma in situ of the breast | Q73872730 | ||
p53, vessel count, and vascular endothelial growth factor expression in human colon cancer | Q74292646 | ||
Vascular endothelial growth factor, interleukin 8, platelet-derived endothelial cell growth factor, and basic fibroblast growth factor promote angiogenesis and metastasis in human melanoma xenografts | Q74314875 | ||
Expression of angiogenesis-related genes and progression of human ovarian carcinomas in nude mice | Q74376048 | ||
Breast carcinoma: vascular density determined using CD105 antibody correlates with tumor prognosis | Q74462138 | ||
Angiogenesis correlates with metastasis in melanoma | Q74464769 | ||
Identification of the KDR tyrosine kinase as a receptor for vascular endothelial cell growth factor | Q24294262 | ||
The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor | Q24328901 | ||
Single-Step Method of RNA Isolation by Acid Guanidinium Thiocyanate–Phenol–Chloroform Extraction | Q25938986 | ||
Vascular endothelial growth factor receptor-2-mediated mitogenesis is negatively regulated by vascular endothelial growth factor receptor-1 in tumor epithelial cells | Q28345678 | ||
Cell contact-dependent activation of alpha3beta1 integrin modulates endothelial cell responses to thrombospondin-1 | Q28647132 | ||
What Is the Evidence That Tumors Are Angiogenesis Dependent? | Q29620029 | ||
Vasculogenic mimicry and tumor angiogenesis | Q30498765 | ||
The vascular endothelial growth factor family: identification of a fourth molecular species and characterization of alternative splicing of RNA. | Q33301664 | ||
Molecular and biological properties of vascular endothelial growth factor | Q33737216 | ||
Vasculogenic mimicry: how convincing, how novel, and how significant? | Q33832972 | ||
Regulation of angiogenesis via vascular endothelial growth factor receptors. | Q33833625 | ||
Vascular channel formation by human melanoma cells in vivo and in vitro: vasculogenic mimicry | Q33874221 | ||
Involvement of integrin alpha V gene expression in human melanoma tumorigenicity | Q34222036 | ||
Tumor angiogenesis and metastasis--correlation in invasive breast carcinoma | Q34570747 | ||
Vascular endothelial growth factor (VEGF)-mediated angiogenesis is associated with enhanced endothelial cell survival and induction of Bcl-2 expression | Q35745301 | ||
Regulation of local host-mediated anti-tumor mechanisms by cytokines: direct and indirect effects on leukocyte recruitment and angiogenesis | Q35764443 | ||
Expression of angiogenesis stimulators and inhibitors in human thyroid tumors and correlation with clinical pathological features | Q35787996 | ||
Expression of vascular endothelial growth factor induces an invasive phenotype in human squamous cell carcinomas | Q35793483 | ||
Tumor vascularity is not a prognostic factor for malignant melanoma of the skin | Q35798557 | ||
Thrombospondin and other possible related matrix proteins in malignant and benign breast disease. An immunohistochemical study | Q35831750 | ||
Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma | Q35833169 | ||
Platelet thrombospondin mediates attachment and spreading of human melanoma cells | Q36225286 | ||
Vascular endothelial growth factor (VEGF) mRNA isoform expression pattern is correlated with liver metastasis and poor prognosis in colon cancer | Q36292182 | ||
Enhanced expression of vascular endothelial growth factor in metastatic melanoma | Q36431187 | ||
Neoangiogenesis and p53 protein in lung cancer: their prognostic role and their relation with vascular endothelial growth factor (VEGF) expression | Q36431673 | ||
Thrombospondin 2 expression is correlated with inhibition of angiogenesis and metastasis of colon cancer | Q36617350 | ||
Expression of vascular endothelial growth factor mRNA in non-small-cell lung carcinomas | Q36617389 | ||
Co-expression of vascular endothelial growth factor (VEGF) and its receptors (flk-1 and flt-1) in hormone-induced mammary cancer in the Noble rat | Q36620026 | ||
Prognostic value of vascular endothelial growth factor (VEGF) in head and neck squamous cell carcinomas | Q36621924 | ||
Immunohistochemical detection of thrombospondin-1 in formalin-fixed, paraffin-embedded tissue | Q38477720 | ||
Melanoma-associated expression of vascular endothelial growth factor and its receptors FLT-1 and KDR. | Q40920837 | ||
The role of thrombospondin-1 in tumor progression and angiogenesis | Q40964893 | ||
Regulation of tumor growth and metastasis by thrombospondin-1. | Q41073499 | ||
Thrombospondin-1 (TSP-1) promotes the invasive properties of human breast cancer | Q41195958 | ||
Analysis of the tumor vasculature and metastatic behavior of xenografts of human melanoma cell lines transfected with vascular permeability factor. | Q41210042 | ||
P433 | issue | 1 | |
P407 | language of work or name | English | Q1860 |
P921 | main subject | microvessel | Q6840468 |
endothelium | Q111140 | ||
patient | Q181600 | ||
P304 | page(s) | 223-235 | |
P577 | publication date | 2001-07-01 | |
P1433 | published in | The American Journal of Pathology | Q4744259 |
P1476 | title | Expresson of vascular endothelial growth factor, its receptors (FLT-1, KDR) and TSP-1 related to microvessel density and patient outcome in vertical growth phase melanomas | |
P478 | volume | 159 |
Q46739137 | A phase 2 trial of dasatinib in patients with locally advanced or stage IV mucosal, acral, or vulvovaginal melanoma: A trial of the ECOG-ACRIN Cancer Research Group (E2607). |
Q51751812 | A randomized phase 2 trial of bevacizumab with or without daily low-dose interferon alfa-2b in metastatic malignant melanoma. |
Q34538284 | Action of Lovastatin (Mevinolin) on an in vitro model of angiogenesis and its co-culture with malignant melanoma cell lines |
Q35146591 | Angiogenesis, lymphangiogenesis, and melanoma metastasis |
Q36346020 | BEAM: a randomized phase II study evaluating the activity of bevacizumab in combination with carboplatin plus paclitaxel in patients with previously untreated advanced melanoma. |
Q57664873 | BRAF and NRAS Mutations Are Frequent in Nodular Melanoma but Are not Associated with Tumor Cell Proliferation or Patient Survival |
Q35234354 | Biomarkers: the useful and the not so useful--an assessment of molecular prognostic markers for cutaneous melanoma |
Q37020248 | Blood vessel maturation in human uveal melanoma: spatial distribution of neovessels and mature vasculature |
Q80270247 | Co-expression of angiogenic markers and associations with prognosis in advanced epithelial ovarian cancer: a Gynecologic Oncology Group study |
Q39850353 | Combined vascular endothelial growth factor receptor and epidermal growth factor receptor (EGFR) blockade inhibits tumor growth in xenograft models of EGFR inhibitor resistance |
Q44567628 | Differential expression of vascular endothelial growth factor-A isoforms at different stages of melanoma progression |
Q33687242 | EMMPRIN promotes melanoma cells malignant properties through a HIF-2alpha mediated up-regulation of VEGF-receptor-2. |
Q21260421 | Effects of THBS3, SPARC and SPP1 expression on biological behavior and survival in patients with osteosarcoma |
Q38873842 | Effects of bisphenol A and 17β-estradiol on vascular endothelial growth factor A and its receptor expression in the non-cancer and cancer ovarian cell lines. |
Q52013947 | Evidence of a bi-phasic effect of thrombospondin-1 on angiogenesis. |
Q36014062 | Expression of Heat Shock Protein 27 in Melanoma Metastases Is Associated with Overall Response to Bevacizumab Monotherapy: Analyses of Predictive Markers in a Clinical Phase II Study |
Q38431670 | Expression of VEGF(xxx)b, the inhibitory isoforms of VEGF, in malignant melanoma |
Q34678882 | Expression of sorafenib targets in melanoma patients treated with carboplatin, paclitaxel and sorafenib |
Q38429857 | Expression of vascular endothelial growth factor in early cutaneous melanocytic lesion progression |
Q36648435 | Glomeruloid microvascular proliferation is associated with p53 expression, germline BRCA1 mutations and an adverse outcome following breast cancer |
Q30445841 | High-resolution ultrasound imaging of cutaneous lesions |
Q24798737 | Highlights on endoglin (CD105): from basic findings towards clinical applications in human cancer |
Q37337431 | Host deficiency in Vav2/3 guanine nucleotide exchange factors impairs tumor growth, survival, and angiogenesis in vivo |
Q50019794 | Human expression patterns: qualitative and quantitative analysis of thrombospondin-1 under physiological and pathological conditions |
Q30475154 | Imaging of melanoma: usefulness of ultrasonography before and after contrast injection for diagnosis and early evaluation of treatment |
Q48138180 | Immunoexpression of endoglin in brain metastasis secondary to malignant melanoma: evaluation of angiogenesis and comparison with brain metastasis secondary to breast and lung carcinomas |
Q47404143 | Immunohistochemical expression of vascular endothelial growth factor (VEGF) and C-KIT in cutaneous melanocytic lesions |
Q60930855 | Immunohistochemical investigation of prognostic biomarkers in resected colorectal liver metastases: a systematic review and meta-analysis |
Q42794629 | Importance of vascular phenotype by basic fibroblast growth factor, and influence of the angiogenic factors basic fibroblast growth factor/fibroblast growth factor receptor-1 and ephrin-A1/EphA2 on melanoma progression |
Q33231917 | Increased laser Doppler flow in skin tumors corresponds to elevated vessel density and reactive hyperemia |
Q33355483 | Inducible nitric oxide synthase expression in melanoma: implications in lymphangiogenesis. |
Q33557480 | Ki-67 expression is superior to mitotic count and novel proliferation markers PHH3, MCM4 and mitosin as a prognostic factor in thick cutaneous melanoma |
Q53500613 | Loss of BMI-1 expression is associated with clinical progress of malignant melanoma. |
Q50791944 | Matricellular TSP-1 as a target of interest for impeding melanoma spreading: towards a therapeutic use for TAX2 peptide. |
Q38196881 | Mechanisms of tumour vascularization in cutaneous malignant melanoma: clinical implications |
Q49924572 | Microvessel Density in Patients with Cutaneous Melanoma: An Up-to-Date Systematic Review and Meta-Analysis |
Q35065032 | Molecular pathogenesis and prognostic factors in endometrial carcinoma |
Q35747435 | Molecular profiling of angiogenesis markers. |
Q38985288 | Monoclonal antibodies to murine thrombospondin-1 and thrombospondin-2 reveal differential expression patterns in cancer and low antigen expression in normal tissues |
Q34128953 | Potential relevance of bell-shaped and u-shaped dose-responses for the therapeutic targeting of angiogenesis in cancer |
Q40117553 | Prognosis in human melanoma: PAR-1 expression is superior to other coagulation components and VEGF. |
Q53188381 | Prognostic importance of the mitotic marker phosphohistone H3 in cutaneous nodular melanoma. |
Q48760414 | Prognostic significance of microvessel density determined by an anti-CD105/endoglin monoclonal antibody in astrocytic tumors: comparison with an anti-CD31 monoclonal antibody. |
Q30499036 | Prognostic value of angiogenesis evaluated with high-frequency and colour Doppler sonography for preoperative assessment of primary cutaneous melanomas: correlation with recurrence after a 5 year follow-up period |
Q33665758 | Quantitative expression of VEGF, VEGF-R1, VEGF-R2, and VEGF-R3 in melanoma tissue microarrays |
Q37385797 | Regulation of nitric oxide signalling by thrombospondin 1: implications for anti-angiogenic therapies |
Q35157766 | Remodeling of the microenvironment by aggressive melanoma tumor cells |
Q38918913 | Role of thrombospondin 1 in liver diseases. |
Q40655691 | Role of thrombospondin-1 expression in colorectal liver metastasis and its molecular mechanism. |
Q33899574 | S100A13 is a new angiogenic marker in human melanoma |
Q41985319 | Semaphorin 3E expression correlates inversely with Plexin D1 during tumor progression. |
Q41983653 | Strong expression of ID1 protein is associated with decreased survival, increased expression of ephrin-A1/EPHA2, and reduced thrombospondin-1 in malignant melanoma |
Q40038149 | The role of VEGF in melanoma progression |
Q34997320 | The vascular-targeting fusion toxin VEGF121/rGel inhibits the growth of orthotopic human bladder carcinoma tumors |
Q43103708 | Thrombospondin-1 expression correlates with angiogenesis in experimental cirrhosis. |
Q42835129 | Thrombospondin-1 is part of a Slug-independent motility and metastatic program in cutaneous melanoma, in association with VEGFR-1 and FGF-2. |
Q37288883 | Tissue biomarkers for prognosis in cutaneous melanoma: a systematic review and meta-analysis |
Q33390467 | Tumor necrosis is associated with increased alphavbeta3 integrin expression and poor prognosis in nodular cutaneous melanomas |
Q44711344 | Tumor specific VEGF-A and VEGFR2/KDR protein are co-expressed in breast cancer |
Q52582783 | Tumour cell expression of interleukin 6 receptor α is associated with response rates in patients treated with sunitinib for metastatic clear cell renal cell carcinoma. |
Q30423356 | VEGFR-2 expression in human melanoma: revised assessment |
Q36447447 | Vascular endothelial growth factor receptor-2 expression is down-regulated by 17beta-estradiol in MCF-7 breast cancer cells by estrogen receptor alpha/Sp proteins |
Q35289963 | Vascular endothelial growth factor regulates melanoma cell adhesion and growth in the bone marrow microenvironment via tumor cyclooxygenase-2. |
Search more.